Latest (Dec 2023) Quarterly:
"Regulatory activities continue to progress
EBR made significant progress regarding key regulatory activities during the quarter. Following the Company’s update in November 2023, EBR is scheduled to submit the final module of its PMA submission in Q3 2024 and is targeting FDA approval in Q1 2025."
Latest (Dec 2023) Quarterly:"Regulatory activities continue to...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
0.010(0.96%) |
Mkt cap ! $325.0M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.08 | $1.00 | $167.8K | 160.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 20408 | 1 |
View Market Depth
| Last trade - 15.31pm 27/06/2024 (20 minute delay) ? |
| EBR (ASX) Chart |